Patent ID: 8557517

Claim:
An in vitro method of assessing the sensitivity of a subject having a cancer selected from breast cancer, sarcoma, ovarian cancer, endometrium cancer, bladder cancer, cervical cancer, prostate cancer, lung cancer, ORL cancer, paediatric tumours, neuroblastoma, glioblastoma multiforme, lymphoma, leukaemia, myeloma, seminoma, Hodgkin's lymphoma or malignant hemopathies to a chemotherapeutic treatment of said cancer comprising determining the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid in a sample from the subject or determining the absence of TLR4 alleles in a sample from the subject, said mutated TLR4 nucleic acid being a wild-type TLR4 nucleic acid comprising a point mutation or a single nucleotide polymorphism (SNP) leading to the substitution of asparagine by glycine at position 299, wherein the presence of said mutated TLR4 nucleic acid or the absence of TLR4 alleles is indicative of a resistance to said chemotherapeutic treatment.